Patients on B-cell depleting therapies at risk for breakthrough COVID-19, severe outcomes - Healio

7/27/2022 12:00:00 AM3 years 7 months ago

Patients with immune-mediated inflammatory diseases receiving B-cell depleting therapies are at risk for COVID-19 regardless of vaccine status, but outpatient use of monoclonal antibodies improves clinical outcomes, according to data.

Patients with immune-mediated inflammatory diseases receiving B-cell depleting therapies are at risk for COVID-19 regardless of vaccine status, but outpatient use of monoclonal antibodies improves cl… [+5083 chars]

full article...